Slide 1: Matthew Kiernan
Matthew Kiernan matthew.kiernan@sydney.edu.au matthew.kiernan@sydney.edu.au Exhibit 99.1
Slide 2: Disclosures & Acknowledgements
Disclosures & Acknowledgements MCK and the University of Sydney have received research funding from Clene to undertake Rescue-ALS RE PWe thank FightMND for its philanthropic support of the TRESCUE-ALS study We thank the study participants and their families for their willingness to support clinical
Slide 3: CNM-Au8 Nanocrystal: Catalytically Active Au Nanocrystals Improve Cellular Energy Production
CNM-Au8® Nanocrystal Clean Surfaced, Highly Faceted Shape Enhances Catalytic Activity Mechanistic Effects Increased Energy Production & Utilization Vertices, Edges, & Facets Key to Catalytic Activity CNM-Au8® | Catalytically Active Au Nanocrystals Improve Cellular Energy Production
Slide 4: Design & Baseline Characteristics
Design & Baseline Characteristics 36-Week Treatment Blinded Treatment with Long-Term Open-Label Follow-Up Baseline wei2 WI Wik WWD WK WG WO e -—- A Screening (oweeks) |= Double-Blind Period =~ Long-Term Open Label Period Baseline Sex Onset Site | Months Value Age 1, (%) 1, (%) from FVC | ALSFRS-R EN
Slide 5: Significant slowing in disease progression & ALSFRS-R 6-point decline
Significant slowing in disease progression & ALSFRS-R 6-point decline
Slide 6: Significant improvement in quality of life
Significant improvement in quality of life
Slide 7: Long-Term Survival in OLE Participants: 70% Improvement vs. Predicted Survival
Long-Term Survival in OLE Participants: 70% Improvement vs. Predicted Survival • All OLE participants. Data censored as of 10-March-2022. Vital status and date of death (as applicable) captured for all subjects withdrawn from the study. ENCALS median survival estimate from baseline characteristics.
Slide 8: Consistent Survival Effect in ex-Placebo Participants
Consistent Survival Effect in ex-Placebo Participants • All OLE participants. Data censored as of 10-March-2022. Vital status and date of death (as applicable) captured for all subjects withdrawn from the study. ENCALS median survival estimate from baseline characteristics.
Slide 9: Conclusions
9 Conclusions Well tolerated and safe in ALS Evidence of CNM-Au8 therapeutic activity: Evidence for improved survival Significant reduction in functional decline Significant slowing in disease progression Improvement in quality of life